1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 Nicastro, G. Franzoni, L. De Chiara, C. Mancin, C.A. Giglio, J.R. Spisni, A. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic 1 90.00 90.00 90.00 1.000 1.000 1.000 C6 H15 N4 O2 1 175.209 y ARGININE L-peptide linking C4 H7 N O4 133.103 y ASPARTIC ACID L-peptide linking C3 H7 N O2 S 121.158 y CYSTEINE L-peptide linking C5 H10 N2 O3 146.144 y GLUTAMINE L-peptide linking C5 H9 N O4 147.129 y GLUTAMIC ACID L-peptide linking C2 H5 N O2 75.067 y GLYCINE peptide linking C6 H10 N3 O2 1 156.162 y HISTIDINE L-peptide linking C6 H13 N O2 131.173 y ISOLEUCINE L-peptide linking C6 H13 N O2 131.173 y LEUCINE L-peptide linking C6 H15 N2 O2 1 147.195 y LYSINE L-peptide linking C5 H11 N O2 S 149.211 y METHIONINE L-peptide linking C9 H11 N O2 165.189 y PHENYLALANINE L-peptide linking C5 H9 N O2 115.130 y PROLINE L-peptide linking C3 H7 N O3 105.093 y SERINE L-peptide linking C11 H12 N2 O2 204.225 y TRYPTOPHAN L-peptide linking C9 H11 N O3 181.189 y TYROSINE L-peptide linking IX Eur.J.Biochem. EJBCAI 0262 0014-2956 270 1969 10.1046/J.1432-1033.2003.03563.X 12709056 Solution Structure of Crotamine, a Na+ Channel Affecting Toxin from Crotalus Durissus Terrificus Venom 2003 UK Toxicon TOXIA6 2043 0041-0101 36 1927 10.1016/S0041-0101(98)00117-2 9839677 The Analgesic Activity of Crotamine,A Neurotoxin from Crotalus Durissus Terrificus Venom:A Biochemical and Pharmacological Study 1998 1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 4902.878 MYOTOXIN 1 nat polymer CROTAMINE no no YKQCHKKGGHCFPKEKICLPPSSDFGKMDCRWRWKCCKKGSG YKQCHKKGGHCFPKEKICLPPSSDFGKMDCRWRWKCCKKGSG A polypeptide(L) n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n SOUTH AMERICAN RATTLESNAKE VENOM OF THE RATTLESNAKE CROTALUS DURISSUS TERRIFICUS sample 8732 CROTALUS DURISSUS TERRIFICUS repository Initial release Derived calculations Other Structure summary Version format compliance 1 0 2003-05-09 1 1 2013-07-24 HELIX DETERMINATION METHOD: AUTHOR PROVIDED. SHEET DETERMINATION METHOD: AUTHOR PROVIDED. PDBE Y PDBE 2001-05-23 REL EXTREMELY RAPID ACTING TOXIN THAT CAUSES MUSCLE NECROSIS. DISABLES PREY BY CAUSING INSTANTANEOUS PARALYSIS OF HIND LIMBS AND DEATH BY PARALYSIS OF THE DIAPHRAGM. THE STRUCTURE WAS DETERMINED USING HOMONUCLEAR 1H-1H 2D NMR ON THE NATURAL TOXIN EXTRACTED FROM THE SNAKE VENOM. LEAST RESTRAINT VIOLATION, LEAST RESIDUAL DEVIATIONS FROM IDEALIZED GEOMETRY 50 26 TOCSY NOESY DQF-COSY 4.0 pH 308 K SEE JRNL CITATION simulated annealing 1MM CROTAMINE, H2O/TFE (70/30) BIOSYM refinement DISCOVER structure solution MSI DISCOVER DISCOVER 600 Bruker DMX 800 Bruker DMX TYR 1 n 1 TYR 1 A LYS 2 n 2 LYS 2 A GLN 3 n 3 GLN 3 A CYS 4 n 4 CYS 4 A HIS 5 n 5 HIS 5 A LYS 6 n 6 LYS 6 A LYS 7 n 7 LYS 7 A GLY 8 n 8 GLY 8 A GLY 9 n 9 GLY 9 A HIS 10 n 10 HIS 10 A CYS 11 n 11 CYS 11 A PHE 12 n 12 PHE 12 A PRO 13 n 13 PRO 13 A LYS 14 n 14 LYS 14 A GLU 15 n 15 GLU 15 A LYS 16 n 16 LYS 16 A ILE 17 n 17 ILE 17 A CYS 18 n 18 CYS 18 A LEU 19 n 19 LEU 19 A PRO 20 n 20 PRO 20 A PRO 21 n 21 PRO 21 A SER 22 n 22 SER 22 A SER 23 n 23 SER 23 A ASP 24 n 24 ASP 24 A PHE 25 n 25 PHE 25 A GLY 26 n 26 GLY 26 A LYS 27 n 27 LYS 27 A MET 28 n 28 MET 28 A ASP 29 n 29 ASP 29 A CYS 30 n 30 CYS 30 A ARG 31 n 31 ARG 31 A TRP 32 n 32 TRP 32 A ARG 33 n 33 ARG 33 A TRP 34 n 34 TRP 34 A LYS 35 n 35 LYS 35 A CYS 36 n 36 CYS 36 A CYS 37 n 37 CYS 37 A LYS 38 n 38 LYS 38 A LYS 39 n 39 LYS 39 A GLY 40 n 40 GLY 40 A SER 41 n 41 SER 41 A GLY 42 n 42 GLY 42 A software_defined_assembly PISA 1 monomeric 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 x,y,z identity operation 0.0000000000 0.0000000000 0.0000000000 A O PHE 12 A O PHE 12 A N LYS 35 A N LYS 35 A O PHE 25 A O PHE 25 A N CYS 36 A N CYS 36 1 A A H1 OD2 TYR ASP 1 29 1.53 2 A A H1 OD1 TYR ASP 1 29 1.54 2 A A OD1 HZ3 ASP LYS 24 35 1.58 3 A A H3 OD2 TYR ASP 1 29 1.56 5 A A OD2 HZ3 ASP LYS 24 35 1.58 5 A A O HG SER SER 22 23 1.59 5 A A H2 OD2 TYR ASP 1 29 1.60 6 A A H2 OD2 TYR ASP 1 29 1.53 6 A A OE1 HH21 GLU ARG 15 33 1.59 9 A A H2 OD2 TYR ASP 1 29 1.53 10 A A O HG SER SER 22 23 1.56 12 A A H1 OD2 TYR ASP 1 29 1.56 13 A A H2 OD2 TYR ASP 1 29 1.59 14 A A H1 OD2 TYR ASP 1 29 1.56 15 A A HG O SER GLY 23 42 1.45 16 A A H2 OD2 TYR ASP 1 29 1.55 17 A A H1 OD2 TYR ASP 1 29 1.59 18 A A HZ2 O LYS GLY 39 42 1.59 21 A A H1 OD2 TYR ASP 1 29 1.58 22 A A OD1 HZ2 ASP LYS 24 35 1.54 22 A A HG O SER LYS 22 39 1.58 23 A A H3 OD2 TYR ASP 1 29 1.55 24 A A HZ2 O LYS GLY 38 42 1.55 26 A A H2 OD2 TYR ASP 1 29 1.54 1 7.91 1.30 111.50 119.41 A A A ND1 CE1 NE2 HIS HIS HIS 5 5 5 N 1 7.91 1.30 111.50 119.41 A A A ND1 CE1 NE2 HIS HIS HIS 10 10 10 N 2 7.91 1.30 111.50 119.41 A A A ND1 CE1 NE2 HIS HIS HIS 5 5 5 N 2 7.83 1.30 111.50 119.33 A A A ND1 CE1 NE2 HIS HIS HIS 10 10 10 N 3 7.86 1.30 111.50 119.36 A A A ND1 CE1 NE2 HIS HIS HIS 5 5 5 N 3 7.88 1.30 111.50 119.38 A A A ND1 CE1 NE2 HIS HIS HIS 10 10 10 N 4 7.86 1.30 111.50 119.36 A A A ND1 CE1 NE2 HIS HIS HIS 5 5 5 N 4 7.96 1.30 111.50 119.46 A A A ND1 CE1 NE2 HIS HIS HIS 10 10 10 N 4 -5.41 0.90 109.00 103.59 A A A CD1 NE1 CE2 TRP TRP TRP 32 32 32 N 5 7.93 1.30 111.50 119.43 A A A ND1 CE1 NE2 HIS HIS HIS 5 5 5 N 6 7.92 1.30 111.50 119.42 A A A ND1 CE1 NE2 HIS HIS HIS 5 5 5 N 6 7.81 1.30 111.50 119.31 A A A ND1 CE1 NE2 HIS HIS HIS 10 10 10 N 7 7.89 1.30 111.50 119.39 A A A ND1 CE1 NE2 HIS HIS HIS 5 5 5 N 7 7.87 1.30 111.50 119.37 A A A ND1 CE1 NE2 HIS HIS HIS 10 10 10 N 7 -5.40 0.90 109.00 103.60 A A A CD1 NE1 CE2 TRP TRP TRP 32 32 32 N 8 7.90 1.30 111.50 119.40 A A A ND1 CE1 NE2 HIS HIS HIS 5 5 5 N 8 7.90 1.30 111.50 119.40 A A A ND1 CE1 NE2 HIS HIS HIS 10 10 10 N 9 7.96 1.30 111.50 119.46 A A A ND1 CE1 NE2 HIS HIS HIS 5 5 5 N 9 7.84 1.30 111.50 119.34 A A A ND1 CE1 NE2 HIS HIS HIS 10 10 10 N 10 7.91 1.30 111.50 119.41 A A A ND1 CE1 NE2 HIS HIS HIS 5 5 5 N 10 7.86 1.30 111.50 119.36 A A A ND1 CE1 NE2 HIS HIS HIS 10 10 10 N 11 7.92 1.30 111.50 119.42 A A A ND1 CE1 NE2 HIS HIS HIS 5 5 5 N 11 7.86 1.30 111.50 119.36 A A A ND1 CE1 NE2 HIS HIS HIS 10 10 10 N 12 7.92 1.30 111.50 119.42 A A A ND1 CE1 NE2 HIS HIS HIS 5 5 5 N 12 7.85 1.30 111.50 119.35 A A A ND1 CE1 NE2 HIS HIS HIS 10 10 10 N 13 7.93 1.30 111.50 119.43 A A A ND1 CE1 NE2 HIS HIS HIS 5 5 5 N 13 7.87 1.30 111.50 119.37 A A A ND1 CE1 NE2 HIS HIS HIS 10 10 10 N 14 7.95 1.30 111.50 119.45 A A A ND1 CE1 NE2 HIS HIS HIS 5 5 5 N 14 7.89 1.30 111.50 119.39 A A A ND1 CE1 NE2 HIS HIS HIS 10 10 10 N 15 7.96 1.30 111.50 119.46 A A A ND1 CE1 NE2 HIS HIS HIS 5 5 5 N 15 7.87 1.30 111.50 119.37 A A A ND1 CE1 NE2 HIS HIS HIS 10 10 10 N 16 7.92 1.30 111.50 119.42 A A A ND1 CE1 NE2 HIS HIS HIS 5 5 5 N 16 7.94 1.30 111.50 119.44 A A A ND1 CE1 NE2 HIS HIS HIS 10 10 10 N 16 -5.47 0.90 109.00 103.53 A A A CD1 NE1 CE2 TRP TRP TRP 32 32 32 N 17 7.93 1.30 111.50 119.43 A A A ND1 CE1 NE2 HIS HIS HIS 5 5 5 N 17 7.95 1.30 111.50 119.45 A A A ND1 CE1 NE2 HIS HIS HIS 10 10 10 N 18 7.93 1.30 111.50 119.43 A A A ND1 CE1 NE2 HIS HIS HIS 5 5 5 N 18 7.90 1.30 111.50 119.40 A A A ND1 CE1 NE2 HIS HIS HIS 10 10 10 N 19 7.90 1.30 111.50 119.40 A A A ND1 CE1 NE2 HIS HIS HIS 5 5 5 N 19 7.96 1.30 111.50 119.46 A A A ND1 CE1 NE2 HIS HIS HIS 10 10 10 N 20 7.95 1.30 111.50 119.45 A A A ND1 CE1 NE2 HIS HIS HIS 5 5 5 N 20 7.88 1.30 111.50 119.38 A A A ND1 CE1 NE2 HIS HIS HIS 10 10 10 N 20 -5.41 0.90 109.00 103.59 A A A CD1 NE1 CE2 TRP TRP TRP 32 32 32 N 21 7.94 1.30 111.50 119.44 A A A ND1 CE1 NE2 HIS HIS HIS 5 5 5 N 21 7.91 1.30 111.50 119.41 A A A ND1 CE1 NE2 HIS HIS HIS 10 10 10 N 22 7.91 1.30 111.50 119.41 A A A ND1 CE1 NE2 HIS HIS HIS 5 5 5 N 22 7.91 1.30 111.50 119.41 A A A ND1 CE1 NE2 HIS HIS HIS 10 10 10 N 23 7.98 1.30 111.50 119.48 A A A ND1 CE1 NE2 HIS HIS HIS 5 5 5 N 23 7.87 1.30 111.50 119.37 A A A ND1 CE1 NE2 HIS HIS HIS 10 10 10 N 24 7.92 1.30 111.50 119.42 A A A ND1 CE1 NE2 HIS HIS HIS 5 5 5 N 24 7.95 1.30 111.50 119.45 A A A ND1 CE1 NE2 HIS HIS HIS 10 10 10 N 25 7.93 1.30 111.50 119.43 A A A ND1 CE1 NE2 HIS HIS HIS 5 5 5 N 25 7.90 1.30 111.50 119.40 A A A ND1 CE1 NE2 HIS HIS HIS 10 10 10 N 25 -5.45 0.90 109.00 103.55 A A A CD1 NE1 CE2 TRP TRP TRP 32 32 32 N 26 7.99 1.30 111.50 119.49 A A A ND1 CE1 NE2 HIS HIS HIS 5 5 5 N 26 7.95 1.30 111.50 119.45 A A A ND1 CE1 NE2 HIS HIS HIS 10 10 10 N 1 A SER 23 -162.53 98.27 1 A LYS 39 -145.96 -63.54 2 A SER 23 -163.74 74.64 2 A MET 28 -98.48 -74.52 2 A CYS 30 -129.97 -103.00 2 A SER 41 -161.61 -51.25 3 A LYS 2 -173.81 -71.92 3 A SER 22 -92.58 56.73 3 A MET 28 -82.17 -111.02 4 A PRO 13 -58.05 173.49 4 A SER 22 -93.45 52.62 4 A SER 23 -150.23 77.88 4 A MET 28 -84.50 -76.26 4 A CYS 30 -114.10 -157.78 4 A LYS 39 -94.28 -68.98 5 A SER 22 -90.50 58.91 5 A SER 23 -162.48 83.20 5 A MET 28 -90.19 -113.63 5 A ASP 29 -110.62 68.64 5 A CYS 30 -142.26 -88.68 5 A LYS 39 -152.11 -145.36 6 A LYS 2 -87.19 -78.26 6 A ASP 29 -151.72 57.65 6 A CYS 30 -123.32 -105.36 6 A SER 41 -75.52 -87.62 7 A SER 22 -90.06 59.43 7 A SER 23 -161.27 85.75 7 A MET 28 -89.50 -77.52 7 A ASP 29 -145.86 43.85 7 A CYS 30 -134.11 -151.21 8 A LYS 2 -132.32 -69.84 8 A SER 22 -96.93 50.46 8 A SER 23 -152.11 78.53 8 A MET 28 -89.34 -121.40 8 A ASP 29 -95.54 48.51 8 A CYS 30 -131.53 -93.39 9 A LYS 2 -90.44 -80.32 9 A SER 22 -85.60 48.90 9 A SER 23 -167.81 72.51 9 A MET 28 -86.01 -86.37 9 A ASP 29 -140.72 50.60 9 A CYS 30 -98.98 -90.92 9 A LYS 39 -113.60 -162.10 10 A LYS 2 -95.17 -71.73 10 A SER 23 -165.99 71.01 10 A MET 28 -117.98 -95.39 10 A CYS 30 -144.85 -77.80 10 A SER 41 -152.68 79.25 11 A LYS 2 -91.65 -72.29 11 A SER 23 -100.42 50.02 11 A MET 28 -71.18 -79.61 11 A ASP 29 -111.05 52.95 11 A ARG 31 -79.96 -165.78 12 A MET 28 -84.88 -108.66 12 A ASP 29 -108.23 66.80 12 A LYS 39 -99.32 -72.58 12 A SER 41 60.73 61.26 13 A LYS 2 -82.87 -86.71 13 A MET 28 -117.91 -93.18 13 A CYS 30 -123.28 -88.93 13 A LYS 39 -135.69 -56.07 14 A SER 22 -87.62 49.44 14 A SER 23 -150.91 51.40 14 A MET 28 -96.92 -118.81 15 A LYS 2 -156.07 -58.15 15 A PRO 21 -93.90 48.52 15 A MET 28 -108.36 -116.01 15 A ASP 29 -91.11 53.51 15 A SER 41 -91.14 53.33 16 A LYS 2 -99.41 -62.10 16 A MET 28 -122.44 -106.30 16 A ASP 29 -95.40 50.67 16 A CYS 30 -157.47 -89.20 16 A LYS 39 -154.86 -50.68 17 A GLU 15 -150.19 -27.74 17 A SER 23 -94.61 47.40 17 A MET 28 -93.04 -112.01 17 A CYS 30 -111.35 -83.24 17 A LYS 38 -104.55 74.88 18 A LYS 16 -90.25 -106.49 18 A MET 28 -90.20 -81.24 18 A ASP 29 -148.06 57.84 18 A CYS 30 -135.13 -102.15 19 A SER 22 -102.80 45.27 19 A SER 23 -160.55 63.73 19 A MET 28 -78.72 -85.28 19 A SER 41 -163.77 72.96 20 A LYS 2 -95.01 -66.41 20 A SER 22 -92.98 58.69 20 A SER 23 -164.20 88.19 20 A MET 28 -107.45 -121.10 20 A ASP 29 -100.24 66.05 20 A CYS 30 -146.55 -142.25 20 A LYS 39 -130.81 -71.51 20 A SER 41 66.23 88.71 21 A LYS 2 -90.47 -66.01 21 A PRO 21 -93.19 52.27 21 A MET 28 -95.58 -76.36 21 A ASP 29 -153.41 58.74 21 A CYS 30 -141.45 -71.23 21 A LYS 39 -74.98 -135.55 22 A LYS 2 -174.27 -69.76 22 A PRO 21 -94.58 55.63 22 A MET 28 -95.34 -115.97 23 A LYS 2 -135.16 -70.16 23 A SER 23 -162.44 80.73 23 A MET 28 -86.98 -108.65 23 A ASP 29 -103.53 50.61 24 A LYS 2 -142.21 -137.68 24 A GLU 15 -154.23 -35.84 24 A MET 28 -83.37 -71.52 24 A SER 41 -153.77 65.14 25 A LYS 2 -107.97 -64.12 25 A LYS 14 -85.12 45.90 25 A GLU 15 -145.41 -29.02 25 A SER 22 -94.70 59.26 25 A SER 23 -166.18 69.16 25 A MET 28 -119.42 -95.95 25 A ASP 29 -107.79 53.71 26 A LYS 2 -88.49 -71.65 26 A GLU 15 -169.29 -32.20 26 A SER 22 -140.05 -66.35 26 A MET 28 -99.43 -120.39 26 A ASP 29 -103.62 40.77 26 A SER 41 -151.16 88.91 MYOTOXIN Solution structure of Crotamine, a neurotoxin from Crotalus durissus terrificus 1 N N A GLN 3 A GLN 3 HELX_P A LYS 7 A LYS 7 1 1 5 disulf 2.003 A CYS 4 A SG CYS 4 1_555 A CYS 36 A SG CYS 36 1_555 disulf 1.996 A CYS 11 A SG CYS 11 1_555 A CYS 30 A SG CYS 30 1_555 disulf 2.748 A CYS 11 A SG CYS 11 1_555 A CYS 36 A SG CYS 36 1_555 disulf 1.999 A CYS 18 A SG CYS 18 1_555 A CYS 37 A SG CYS 37 1_555 TOXIN TOXIN, SODIUM CHANNEL AFFECTING TOXIN, VENOM A LEU 19 A LEU 19 1 A PRO 20 A PRO 20 7.69 A LEU 19 A LEU 19 2 A PRO 20 A PRO 20 0.73 A LEU 19 A LEU 19 3 A PRO 20 A PRO 20 1.29 A LEU 19 A LEU 19 4 A PRO 20 A PRO 20 5.03 A LEU 19 A LEU 19 5 A PRO 20 A PRO 20 2.97 A LEU 19 A LEU 19 6 A PRO 20 A PRO 20 7.71 A LEU 19 A LEU 19 7 A PRO 20 A PRO 20 8.67 A LEU 19 A LEU 19 8 A PRO 20 A PRO 20 5.05 A LEU 19 A LEU 19 9 A PRO 20 A PRO 20 9.17 A LEU 19 A LEU 19 10 A PRO 20 A PRO 20 5.72 A LEU 19 A LEU 19 11 A PRO 20 A PRO 20 4.70 A LEU 19 A LEU 19 12 A PRO 20 A PRO 20 8.83 A LEU 19 A LEU 19 13 A PRO 20 A PRO 20 7.47 A LEU 19 A LEU 19 14 A PRO 20 A PRO 20 5.39 A LEU 19 A LEU 19 15 A PRO 20 A PRO 20 10.10 A LEU 19 A LEU 19 16 A PRO 20 A PRO 20 5.49 A LEU 19 A LEU 19 17 A PRO 20 A PRO 20 8.21 A LEU 19 A LEU 19 18 A PRO 20 A PRO 20 6.96 A LEU 19 A LEU 19 19 A PRO 20 A PRO 20 7.72 A LEU 19 A LEU 19 20 A PRO 20 A PRO 20 9.31 A LEU 19 A LEU 19 21 A PRO 20 A PRO 20 8.87 A LEU 19 A LEU 19 22 A PRO 20 A PRO 20 6.09 A LEU 19 A LEU 19 23 A PRO 20 A PRO 20 9.87 A LEU 19 A LEU 19 24 A PRO 20 A PRO 20 6.07 A LEU 19 A LEU 19 25 A PRO 20 A PRO 20 2.64 A LEU 19 A LEU 19 26 A PRO 20 A PRO 20 4.43 MYXC_CRODU UNP 1 P01475 1 42 1H5O 1 42 P01475 A 1 1 42 3 anti-parallel anti-parallel A GLY 9 A GLY 9 A PHE 12 A PHE 12 A LYS 35 A LYS 35 A LYS 38 A LYS 38 A ASP 24 A ASP 24 A PHE 25 A PHE 25 1 P 1